I-SPY 2: Durvalumab plus Olaparib and Paclitaxel Triplet in High-Risk Breast Cancer “Graduates” to Phase 3 Study
In the I-SPY 2 clinical trial presented at the 2020 AACR annual meeting, the combination of durvalumab, olaparib, and paclitaxel, used as neoadjuvant therapy, improved the pathological complete responses of patients with high-risk HER2-negative stage II or III breast cancer, as well as in those with triple-negative breast cancer, compared with chemotherapy alone. These results signal that the triplet regimen has “graduated” for further study in a phase 3 clinical trial.
Chemotherapy-Free PARP Inhibitor Combination Improves Outcomes versus Single-Agent PARP Inhibitor in Recurrent Ovarian Cancer
Individualized Starting Dose of Niraparib Is Recommended in First-Line Maintenance Setting in Recurrent Ovarian Cancer
In the PRIMA study, patients with recurrent ovarian cancer receiving maintenance therapy with an individualized dose of niraparib had similar efficacy compared with placebo as patients receiving a fixed dose of niraparib while experiencing half as many thrombocytopenic events.
In a pooled analysis of 2 randomized trials of rucaparib for the treatment of patients with recurrent high-grade ovarian cancer, deleterious BRCA mutations were identified in 71% of patients with responses lasting at least 1 year but in only 52% of short-term responders.
Finding a Pathogenic Mutation on Genetic Testing Does Not Add to Stress or Anxiety in Women with Newly Diagnosed Ovarian Cancer
In a study of 76 English-speaking women with newly diagnosed ovarian cancer who underwent genetic testing, those found to have a pathogenic mutation did not report increased levels of stress, anxiety, or depression compared with pre-genetic testing. Those testing negative for mutations saw their posttest anxiety levels decline.
As we learn more about the complicated behavior of the COVID-19 virus, we have come to understand that overactivation of the patient’s own immune system can often be the most dangerous factor. In this webcast, top cancer experts discuss the latest studies investigating using anti-cancer therapies as treatments for COVID-19. What are some of the options and where does the research stand today?
The COVID-19 pandemic has led to the elimination of several restrictions on telehealth and infusion therapy in the home setting. In this webcast, a panel of experts discuss the short- and long-term prospects for in-home infusion for patients with cancer. What are the benefits and drawbacks?
Rucaparib As Maintenance Therapy Delays Progression in Patients with Platinum-Sensitive Recurrent Ovarian Cancer
Niraparib plus Bevacizumab Combination Leads to Improved PFS Without Cumulative Toxicity in Advanced Ovarian Cancer
Page 1 of 32
Results 1 - 10 of 315
Results 1 - 10 of 315